Logo image of CJJD

CHINA JO-JO DRUGSTORES HOLDI (CJJD) Stock Fundamental Analysis

NASDAQ:CJJD - Nasdaq - KYG2124G1203 - Common Stock - Currency: USD

1.53  +0.07 (+4.79%)

Fundamental Rating

1

Taking everything into account, CJJD scores 1 out of 10 in our fundamental rating. CJJD was compared to 40 industry peers in the Consumer Staples Distribution & Retail industry. Both the profitability and financial health of CJJD have multiple concerns. CJJD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CJJD had negative earnings in the past year.
In the past year CJJD has reported a negative cash flow from operations.
CJJD had negative earnings in each of the past 5 years.
CJJD had a negative operating cash flow in each of the past 5 years.
CJJD Yearly Net Income VS EBIT VS OCF VS FCFCJJD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M

1.2 Ratios

CJJD's Return On Assets of -5.93% is on the low side compared to the rest of the industry. CJJD is outperformed by 76.92% of its industry peers.
CJJD has a worse Return On Equity (-26.03%) than 74.36% of its industry peers.
Industry RankSector Rank
ROA -5.93%
ROE -26.03%
ROIC N/A
ROA(3y)-10.23%
ROA(5y)-8.83%
ROE(3y)-52.56%
ROE(5y)-43.49%
ROIC(3y)N/A
ROIC(5y)N/A
CJJD Yearly ROA, ROE, ROICCJJD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80 -100

1.3 Margins

The Gross Margin of CJJD (20.24%) is worse than 61.54% of its industry peers.
In the last couple of years the Gross Margin of CJJD has declined.
The Profit Margin and Operating Margin are not available for CJJD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.87%
GM growth 5Y-2.92%
CJJD Yearly Profit, Operating, Gross MarginsCJJD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

More info and screens

1

2. Health

2.1 Basic Checks

CJJD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CJJD has been increased compared to 1 year ago.
The number of shares outstanding for CJJD has been increased compared to 5 years ago.
Compared to 1 year ago, CJJD has a worse debt to assets ratio.
CJJD Yearly Shares OutstandingCJJD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
CJJD Yearly Total Debt VS Total AssetsCJJD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

CJJD has an Altman-Z score of 0.36. This is a bad value and indicates that CJJD is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.36, CJJD is doing worse than 87.18% of the companies in the same industry.
CJJD has a Debt/Equity ratio of 1.54. This is a high value indicating a heavy dependency on external financing.
CJJD's Debt to Equity ratio of 1.54 is on the low side compared to the rest of the industry. CJJD is outperformed by 79.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.54
Debt/FCF N/A
Altman-Z 0.36
ROIC/WACCN/A
WACC3.1%
CJJD Yearly LT Debt VS Equity VS FCFCJJD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

CJJD has a Current Ratio of 1.05. This is a normal value and indicates that CJJD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.05, CJJD is in line with its industry, outperforming 43.59% of the companies in the same industry.
CJJD has a Quick Ratio of 1.05. This is a bad value and indicates that CJJD is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.77, CJJD is in the better half of the industry, outperforming 64.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.05
Quick Ratio 0.77
CJJD Yearly Current Assets VS Current LiabilitesCJJD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

CJJD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 91.08%, which is quite impressive.
Looking at the last year, CJJD shows a decrease in Revenue. The Revenue has decreased by -4.87% in the last year.
The Revenue has been growing slightly by 7.52% on average over the past years.
EPS 1Y (TTM)91.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.01%
Revenue 1Y (TTM)-4.87%
Revenue growth 3Y5.1%
Revenue growth 5Y7.52%
Sales Q2Q%-9.44%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CJJD Yearly Revenue VS EstimatesCJJD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
CJJD Yearly EPS VS EstimatesCJJD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CJJD. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CJJD Price Earnings VS Forward Price EarningsCJJD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CJJD Per share dataCJJD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CJJD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHINA JO-JO DRUGSTORES HOLDI

NASDAQ:CJJD (2/26/2025, 4:00:36 PM)

1.53

+0.07 (+4.79%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)03-01 2022-03-01/amc
Earnings (Next)N/A N/A
Inst Owners0.37%
Inst Owner Change0%
Ins Owners40.89%
Ins Owner Change0%
Market Cap9.46M
Analysts0
Price TargetN/A
Short Float %0.4%
Short Ratio0.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.06
P/FCF N/A
P/OCF N/A
P/B 0.44
P/tB 0.51
EV/EBITDA N/A
EPS(TTM)-2.38
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-2.42
FCFYN/A
OCF(TTM)-2.24
OCFYN/A
SpS23.81
BVpS3.47
TBVpS2.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.93%
ROE -26.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.24%
FCFM N/A
ROA(3y)-10.23%
ROA(5y)-8.83%
ROE(3y)-52.56%
ROE(5y)-43.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.87%
GM growth 5Y-2.92%
F-Score3
Asset Turnover1.56
Health
Industry RankSector Rank
Debt/Equity 1.54
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 118.6%
Cap/Sales 0.78%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.05
Quick Ratio 0.77
Altman-Z 0.36
F-Score3
WACC3.1%
ROIC/WACCN/A
Cap/Depr(3y)61.56%
Cap/Depr(5y)65.76%
Cap/Sales(3y)0.33%
Cap/Sales(5y)0.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)91.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.01%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-4.87%
Revenue growth 3Y5.1%
Revenue growth 5Y7.52%
Sales Q2Q%-9.44%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y69.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-163.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-151.88%
OCF growth 3YN/A
OCF growth 5YN/A